首页> 外文OA文献 >PND120 - TREATMENT DECISIONS ABOUT FIRST-LINE DISEASE-MODIFYING TREATMENTS (DMTS) IN RELAPSING REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW OF PATIENT NEEDS AND PREFERENCES

【2h】

PND120 - TREATMENT DECISIONS ABOUT FIRST-LINE DISEASE-MODIFYING TREATMENTS (DMTS) IN RELAPSING REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW OF PATIENT NEEDS AND PREFERENCES

机译：PND120 - 复发延迟多发性硬化症的第一线疾病修饰治疗（DMTS）的治疗决策：对患者需求和偏好的系统审查

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
LA Visser; C Uyl-de Groot; K Redekop;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. [J] . Michael Hutchinson, Robert J Fox, Eva Havrdova, Current medical research and opinion . 2014,第4期

机译：BG-12（富马酸二甲酯）和其他缓解疾病的疗法治疗复发性多发性硬化症的疗效和安全性：系统评价和混合治疗比较。
2. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. [J] . Michael Hutchinson, Robert J Fox, Eva Havrdova, Current medical research and opinion . 2014,第4期

机译：BG-12（富马酸二甲酯）和其他疾病改性治疗的疗效和安全性用于治疗重复多发性硬化剂：系统评价和混合治疗比较。
3. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis [J] . Siddiqui Mohd Kashif, Khurana Inderpreet Singh, Budhia Sangeeta, Current medical research and opinion . 2018,第8期

机译：系统文献综述和网络荟萃分析的克拉替宾片与替代疾病改性治疗，用于复发 - 延长多发性硬化症
4. Microstructural Modulations in the Hippocampus Allow to Characterizing Relapsing-Remitting Versus Primary Progressive Multiple Sclerosis [C] . Lorenza Brusini, Ilaria Boscolo Galazzo, Muge Akinci, International Workshop on Brain-Lesion;Medical Image Computing and Computer Assisted Intervention Conference . 2020

机译：海马中的微观结构调制允许表征复发 - 延长与初级进步多发性硬化
5. Patient preferences and economic considerations in treatment decisions for multiple sclerosis. [D] . Prosser, Lisa Alison. 2000

机译：多发性硬化症治疗决策中的患者偏好和经济考虑。
6. Evaluating Treatment Patterns Relapses Healthcare Resource Utilization and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients [O] . Leorah Freeman, Arianna Kee, Marc Tian, 2021

机译：评估治疗模式复发医疗资源利用率和与DMT-Naïve患者多发性硬化症的疾病修饰治疗相关的成本
7. PND52 Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients [O] . Soini E., Asseburg C., Sumelahti M.L. 2014

机译：芬兰复发缓解型多发性硬化症（RRMS）患者的一线疾病改良治疗（DMT）与最佳支持治疗（Bsc）的PND52成本-效用分析（cua）

PND120 - TREATMENT DECISIONS ABOUT FIRST-LINE DISEASE-MODIFYING TREATMENTS (DMTS) IN RELAPSING REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW OF PATIENT NEEDS AND PREFERENCES

著录项

引文网络

相似文献

相关主题

期刊订阅